ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...

ProKidney (PROK) shares soared as much as 660% this morning after the biotech firm said its Rilparencel showed promising ...

ProKidney Corp. (NASDAQ:PROK) saw its stock skyrocket 115% following the release of positive topline results from its Phase 2 ...

ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with ...

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...

ProKidney shares jumped 56% in premarket trading after reporting positive topline results from a select population group in a Phase 2 trial evaluating rilparencel in patients with chronic kidney ...

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...

Shares of ProKidney rose 558% after it reported favorable results from a study of its lead drug candidate, rilparencel, in patients with chronic kidney disease and diabetes.

ProKidney’s Rilparencel shows promise for CKD patients, with Phase 2 data expected in 2025. Learn why PROK stock is a “Buy” with multiple catalysts ahead.

We are confident that this strategic shift in our Phase 3 program is the most expeditious and resource efficient approach to bring rilparencel to market in the U.S., our highest priority market ...

Rilparencel has received a Regenerative Medicine Advanced Therapy (RMAT) designation, it should be noted. June 2024 Company Presentation. Rilparencel is targeting Stage 3b/4 CKD caused by type 2 ...

FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel FDA also confirmed ...